Preclinical Ophthalmic Research

Ophtalmic Drug Development

As a multidisciplinary contract research organization, Toxikon is focused on evaluating the safety and toxicity of biologics, pharmaceuticals and medical devices. One of Toxikon’s specialties is conducting studies focused on the treatment of ocular diseases. Our experienced study directors will provide you with the expertise in ophthalmology models and endpoints for your ocular drug program.

Ophthalmic Development Capabilities

While our reputation has been built on our vast toxicology and chemistry experience,Toxikon’s Ocular Program capabilities include:

• Intra-vitreal injections, stereotaxic surgery
• Aesthesiometry, tonometry, pupilometry; and electroretinography (ERG)
• Slit-Lamp exams and Draize and McDonald-Shadduck scoring systems Direct and indirect ophthalmoscopy
• Anterior/posterior segment and fundus photography
• Ocular tissue dissection, distribution and PK/PD/ADME
• Retina/choroid flat-whole mounting, confocal microscopy, and RGC quantitation
• Ocular histology/pathology and clinical support
• Stereo and fluorescent microscopy
• Optic nerve damage assessment
• Specialized surgeries (e.g. episcleral vein injections to induce elevated IOP)

These studies in small and large animal models, include acute irritation, ocular distribution (PK/PD), acute and repeat dose toxicity, implantation, drug screening and drug efficacy.  We can also customize studies for targeted therapeutics, such as dry eye and corneal wound healing, inflammation and uveitis, neovascularization and age-related macular degeneration, glaucoma and neuroprotection.